Industry News

• SELLAS Life Sciences announces pricing of $15 million public offering  SELLAS Life Sciences announced pricing of an underwritten public offering of (i) 26,367,200 shares of common stock together with common stock warrants to purchase 26,367,200 shares of common stock and (ii) 73,632,800 pre-funded warrants exercisable for one share of common stock.
  June 14, 2019  
• Theravance and Mylan expand YUPELRI® (revefenacin) commercialization agreement to China  Theravance and Mylan announced the expansion of the companies' current development and commercialization agreement for nebulized revefenacin to include China and certain adjacent territories. Revefenacin, marketed as YUPELRI® in the U.S., is a LAMA approved for treatment of COPD.
  June 14, 2019  
• Kura Oncology announces positive phase 2 trial of tipifarnib in peripheral T-cell lymphoma  Kura Oncology announced updated interim data from the ongoing Phase 2 clinical trial of its lead drug candidate, tipifarnib, in patients with relapsed or refractory peripheral T-cell lymphoma. Tipifarnib was generally well-tolerated in this Phase 2 trial.
  June 14, 2019  
• CytoDyn raises over $12 million in new capital from private and public warrant offers   CytoDyn announced it raised $9.1 million from its recently completed public warrant tender offer. Combined with $3 million raised from a private warrant exercise offer in May, new capital injected on a gross basis in the last five weeks now totals over $12 million.
  June 14, 2019  
• Enanta Pharmac announces topline results showing EDP-938 achieved its endpoints  Enanta Pharmaceuticals announced topline results demonstrated that EDP-938 achieved highly statistically significant reductions in viral load and in resolution of clinical symptoms compared to placebo in its Phase 2a human challenge study of EDP-938 in healthy adults infected with RSV.
  June 14, 2019  
• ArQule announces clinical proof-of-concept data from ongoing phase 1 study  ArQule announced preliminary results from the Company’s phase 1 dose escalation study for ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase in patients with relapsed or refractory hematologic malignancies.
  June 14, 2019  
• GBT announces updated efficacy data from all patients Enrolled in phase 3 HOPE study  Global Blood Therapeutics announced new results from its Phase 3 HOPE Study of voxelotor in patients ages 12 and older with sickle cell disease. The findings from 274 adolescents and adults treated with voxelotor showed the HOPE Study met its primary endpoint of an improvement in hemoglobin.
  June 14, 2019  
• Seres Therapeics anounces pricing of public offering of common stock  Seres Therapeutics announced pricing of an underwritten public offering of 26,666,667 shares of its common stock, at a public offering price of $2.25 per share. Seres granted underwriters a 30-day option to purchase up to an additional 2,666,666 shares of its common stock.
  June 14, 2019  
• Phase III PEMPHIX study showed positive results from Roche’s Mabthera/Rituxan (rituximab)  Roche announced positive topline results from the Roche-sponsored phase III PEMPHIX study, evaluating efficacy and safety of MabThera®/Rituxan® (rituximab) compared to mycophenolate mofetil in adults with moderate to severe pemphigus vulgaris.
  June 13, 2019  
• First patient dosed with gevokizumab in collaborator clinical study  XOMA announced that gevokizumab is now actively progressing in a Novartis oncology development program. The antibody candidate is being evaluated to determine the appropriate dose, as well as preliminary safety and efficacy, in combination with standard of care anti-cancer therapies.
  June 13, 2019  

   (next 10 articles)